Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease

Blood

Volumn 93, Issue 5, 1999, Pages 1697-1706

  Dallas, Sarah L ^a   Garrett, I Ross ^b   Oyajobi, Babatunde O ^b   Dallas, Mark R ^b   Boyce, Brendan F ^b   Bauss, Frieder ^b   Radl, Jiri ^b   Mundy, Gregory R ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IBANDRONIC ACID; IMMUNOGLOBULIN G2B;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; MORPHOMETRICS; MOUSE; MYELOMA; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0033105769     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.5.1697     Document Type: Article

References (33)

1. Jantunen E, Laakso M: Bisphosphonates in multiple myeloma: Current status; future perspectives. Br J Haematol 93:501, 1996
2. Bataille R: Management of myeloma with bisphosphonates. N Engl J Med 334(8):529, 1996
3. Berenson JR: Bisphosphonates in multiple myeloma. Cancer 80(8):1661, 1997 (Suppl)
4. Mundy GR, Yoneda T: Bisphosphonates as anti-cancer drugs. N Engl J Med 339(6):398, 1998
5. Berenson J, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight R: Efficacy of Pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488, 1996
6. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I: Randomized, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340:1049, 1994
7. Laakso M, Lahtinen R, Virkkunen P, Elomaa I: Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Br J Haematol 87:725, 1994
8. McCloskey EV, Maclennan CM, Drayson MT, Chapman C, Dunn J, Kanis JA: A randomized trial of the effect of clodronate in multiple myeloma. Br J Haematol 100:317, 1998
9. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T: The bisphosphonate risedronate reduces metastatic human breast cancer burden in nude mice. Cancer Res 55:3551, 1995
10. Shipman CM, Rogers MJ, Apperley JF, Russell RGG, Croucher P: Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumor activity. Br J Haematol 98:665, 1997
11. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A: In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12:220, 1998
12. Brincker H, Westin J, Abildgaard N, Gimsing P, Turesson I, Hedenus M, Ford J, Kandra A: Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double blind placebo controlled trial. Br J Haematol 101:280, 1998
13. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 16(2):593, 1998
14. Radl J, De Glopper E, Schuit HRE, Zurcher C: Idiopathic paraproteinemia: II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol 122:609, 1979
15. Croese JW, Vas Nunes CM, Radl J, Van den Enden-Vieveen MHM, Brondijk RJ, Boersma WJA: The 5T2 mouse multiple myeloma model: Characterization of 5T2 cells within the bone marrow. Br J Cancer 56:555, 1987
16. Radl J, Willem Croese J, Zurcher C, Van den Enden-Vieveen MHM, de Leeuw AM: Animal model of human disease: Multiple myeloma. Am J Pathol 132(3):593, 1988
17. Manning LS, Berger JD, O'Donoghue HL, Sheridan GN, Claringbold PG, Turner JH: A model of multiple myeloma: Culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse. Br J Cancer 66:1088, 1992
18. Garrett IR, Dallas S, Radl J, Mundy GR: A murine model of myeloma bone disease. Bone 20:515, 1997
19. Mühlbacher RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, Heisch H: BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003, 1991
20. Bauss F: Ibandronate in malignant bone diseases and osteoporosis - preclinical results. Onkologie 20:204, 1997
21. Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, De Clerck YA, Mundy GR: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 99:2509, 1997
22. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR: Evidence for a causal role for parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98:1544, 1996
23. Hughes DE, Tiffee JC, Li HH, Mundy GR, Boyce BF: Estrogen promotes apoptosis of murine osteoclasts-mediated by TGFβ. Nature Med 7:1132, 1996
24. Dallas SL, Miyazono K, Skerry TM, Mundy GR, Bonewald LF: Dual role for the latent TGFβ binding protein in storage of latent TGFβ in the extracellular matrix and as a structural matrix protein. J Cell Biol 131:539, 1995
25. Dawson-Saunders B, Trapp RG: Methods for analyzing survival data, in Dawson-Saunders N, Trapp RG (eds): Basic and Clinical Biostatistics, ed. 2. Norwolk, CT, Appelton and Lange, 1994, p 188
26. Fleisch H: Bisphosphonates. Pharmacology and use in the treatment of tumor-induced hypercalcemia and metastatic bone disease. Drugs 42:919, 1991
27. Michigami T, Williams PJ, Dallas M, Mundy GR, Yoneda T: Bisphosphonate may increase metastasis to soft tissue sites in breast cancer and B-cell lymphoma. J Bone Miner Res 12:S106, 1997 (Suppl 1)
28. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden LA, Plechazyck M, Bataille R: Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation of interleukin-6. Blood 73:517, 1989
29. Westendorf JJ, Ahmann GJ, Armitage RJ, Spriggs MK, Lust JA, Greipp PR, Katzmann JA, Jelinek DF: CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol 152:117, 1994
30. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC: CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 85:1903, 1995
31. Radl J, Croese JW, Zurcher C, Van den Enden-Vieveen MHM, Brondijk RJ, Kazil M, Haaijman JJ, Reitsma PH, Bijvoet OLM: Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer 55:1030, 1985
32. Croese JW, Zurcher C, Van den Enden-Vieveen MHM, Radl J: Effect of long term treatment with the bisphosphonate APD on 5T2 mouse multiple myeloma, in Radl J, and Van Camp B (eds): Monoclonal Gammopathies III: Clinical significance and basic mechanisms. Topics in aging research in Europe, vol 14. Leiden, The Netherlands, EURAGE, 1991, p 199
33. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10(10): 1478, 1995